CNA/
Articles/
2604003575
  • Open Access
  • Article

Deaths Involving Gabapentin and Pregabalin, Scotland, 2000–2024: A Descriptive Account

  • John Martin Corkery 1,*,   
  • Amira Guirguis 1,2,   
  • Fabrizio Schifano 1

Received: 26 Dec 2025 | Revised: 25 Feb 2026 | Accepted: 03 Apr 2026 | Published: 21 Apr 2026

Abstract

Gabapentin and pregabalin, while prescribed for conditions like neuropathic pain and epilepsy, have shown increasing misuse, raising concerns about their potential for harm, especially with other central nervous system (CNS) depressants. This study describes the characteristics of deaths associated with gabapentin and/or pregabalin in Scotland from 2000 to 2024, using data provided by the National Records of Scotland. The analysis included socio-demographics, drugs implicated, and cause and manner of death. Out of 3813 deaths where gabapentin or pregabalin was listed in the Poison field, the number of deaths increased from 2008 to 2019, with a slight recovery in 2023 after falls in 2020 and 2021. The majority (65.6%) of deaths involved males, and the mean age at death was 43.0 years. Polypharmacy was common, with 98.9% of cases involving at least one other drug, typically opioids or benzodiazepines. Accidental poisoning was the most common cause of death (90.7%), with 4.7% attributed to suicide. There was no death involving a gabapentinoid on its own. Scottish trends in prescribing and deaths align with concerns about rising gabapentinoid misuse and associated harms across the United Kingdom. The findings underscore the risk of polypharmacy, particularly with CNS depressants, and highlight the need for cautious prescribing and greater awareness of the dangers of co-consumption.

References 

  • 1.

    ACMD. ACMD Advice on Pregabalin and Gabapentin; Advisory Council on the Misuse of Drugs: London, UK, 2016. Available online: https://www.gov.uk/government/publications/advice-on-the-anticonvulsant-drugs-pregabalin-and-gabapentin (accessed on 23 December 2025).

  • 2.

    Durand, L.; Arensman, E.; Corcoran, P.; et al. Harms Associated with Prescription Drug Misuse in Ireland: A National Observational Study of Trends in Treatment Demand, Non-Fatal Intentional Drug Overdoses and Drug-Related Deaths 2010–2020. Drug Alcohol Depend. 2025, 272, 112669. https://doi.org/10.1016/j.drugalcdep.2025.112669.

  • 3.

    EUDA. Drug-induced deaths—the current situation in Europe (European Drug Report 2025). Available online: https://www.euda.europa.eu/publications/european-drug-report/2025/drug-induced-deaths_en (accessed on 23 December 2025).

  • 4.

    Durand, L.; O’Kane, A.; Tierney, J.; et al. Gabapentinoids in Ireland 2010–2020: An Observational Study of Trends in Gabapentinoid Prescribing, Law Enforcement Drug Seizures and Postmortem Toxicology. Br. J. Clin. Pharmacol. 2024, 90, 987–995. https://doi.org/10.1111/bcp.15984.

  • 5.

    Bonnet, U.; Auwärter, V.; Scherbaum, N. Gabapentinoid-Related Deaths: An Alarming Global Trend or Just a Special Challenge within the Long Tail of the Giant Opioid Epidemic? Lancet Reg. Health Am. 2022, 11, 100309. https://doi.org/10.1016/j.lana.2022.100309.

  • 6.

    Ciesluk, B.; Inglis, D.G.; Parke, A.; et al. Systematic Review: The Relationship between Gabapentinoids, Etizolam, and Drug-Related Deaths in Scotland. PLoS ONE 2024, 19, e0310655. https://doi.org/10.1371/journal.pone.0310655.

  • 7.

    FDA. Neurontin, Gralise, Horizant (Gabapentin) and Lyrica, Lyrica CR (Pregabalin): Drug Safety Communication—Serious Breathing Problems. Available online: https://www.fda.gov/safety/medical-product-safety-information/neurontin-gralise-horizant-gabapentin-and-lyrica-lyrica-cr-pregabalin-drug-safety-communication (accessed on 23 December 2025).

  • 8.

    FDA. Supplement Approval, Letter to Upjohn Regarding New Safety Information to Be Added to the Labels for Lyrica®; U.S. Food and Drug Administration: Silver Spring, MD, USA, 2025. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/021446Orig1s046,%20022488Orig1s022ltr.pdf (accessed on 23 December 2025).

  • 9.

    Humpert, S.R.; Reveles, K.R.; Bhakta, K.; et al. Association of Gabapentinoids with Opioid-Related Overdose in the Inpatient Setting: A Single-Center Retrospective Case–Control Study. Hosp. Pharm. 2024, 59, 188–197. https://doi.org/10.1177/00185787231206522.

  • 10.

    Soeiro, T.; Uras, M.; Jouanjus, É.; et al. High-Dose Use of Pregabalin and Gabapentin in France: A Retrospective, Population-Based Cohort Study. Lancet Reg. Health Eur. 2025, 57, 101424. https://doi.org/10.1016/j.lanepe.2025.101424.

  • 11.

    Babu, K.M. Gabapentinoid Poisoning and Withdrawal. Available online: https://www.uptodate.com/contents/gabapentinoid-poisoning-and-withdrawal (accessed on 23 December 2025).

  • 12.

    Kaye, A.D.; Cassagne, G.; Abbott, B.M.; et al. Emerging Clinical Roles of Gabapentin and Adverse Effects, Including Weight Gain, Depression, Suicidal Thoughts and Increased Risk of Opioid Related Overdose and Respiratory Depression: A Narrative Review. Curr. Pain Headache Rep. 2025, 29, 95. https://doi.org/10.1007/s11916-025-01410-2.

  • 13.

    Johansen, M.E.; Maust, D.T. Update to Gabapentinoid Use in the United States, 2002–2021. Ann. Fam. Med. 2024, 22, 45–49. https://doi.org/10.1370/afm.3052.

  • 14.

    Pain News Network. Gabapentinoids Still Overprescribed Despite Warnings; Pain News Network: Monrovia, CA, USA, 2024. Available online: https://www.painnewsnetwork.org/stories/2024/1/23/gabapentinoids-still-overprescribed-despite-warnings (accessed on 23 December 2025).

  • 15.

    Yuen, A.S.C.; Chen, B.; Chan, A.Y.L.; et al. Use of Gabapentinoid Treatment and the Risk of Self Harm: Population Based Self Controlled Case Series. BMJ 2025, 389, e081627. https://doi.org/10.1136/bmj-2024-081627.

  • 16.

    Montastruc, F.; Loo, S.Y.; Renoux, C. Trends in First Gabapentin and Pregabalin Prescriptions in Primary Care in the United Kingdom, 1993–2017. JAMA 2018, 320, 2149–2151. https://doi.org/10.1001/jama.2018.12358.

  • 17.

    UK Statutory Instruments. Misuse of Drugs Act 1971 (Amendment) Order 2018. Available online: https://www.legislation.gov.uk/uksi/2018/1356/contents/made (accessed on 23 December 2025).

  • 18.

    Hockenhull, J.; Wood, D.M.; Dargan, P.I. Online Availability of Gabapentin and Pregabalin and the Impact of Legal Reclassification in the United Kingdom. Drugs Educ. Prev. Policy 2022, 30, 222–226. https://doi.org/10.1080/09687637.2020.1799943.

  • 19.

    Kamerman, P. Rescheduling Gabapentinoids Had Negligible Effects on Prescribing Behaviour by General Practitioners in England. Pharmacoepidemiol. Drug Saf. 2023, 32, 924–932. https://doi.org/10.1002/pds.5628.

  • 20.

    Office for National Statistics (ONS). Deaths Related to Drug Poisoning in England and Wales: 2023 Registrations. Available online: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsrelatedtodrugpoisoninginenglandandwales/2023registrations (accessed on 23 December 2025).

  • 21.

    NISRA. Drug Related and Drug Misuse Deaths 2013–2023; Northern Ireland Statistics & Research Agency: Belfast, UK, 2025. Available online: https://www.nisra.gov.uk/publications/drug-related-and-drug-misuse-deaths-2013–2023 (accessed on 23 December 2025).

  • 22.

    NRS. Drug Related Deaths in Scotland in 2023; National Records of Scotland: Edinburgh, UK, 2024. Available online: https://www.nrscotland.gov.uk/publications/drug-related-deaths-in-scotland-in-2023/ (accessed on 23 December 2025).

  • 23.

    Alrahmani, A.; Azeez, M.; Baker, S.; et al. Impact of Gabapentinoids’ Reclassification Policy and COVID 19 on Gabapentinoids’ Utilization Pattern and Their Associated Mortality in Scotland and Northern Ireland: A Segmental Regression Analysis. Expert Rev. Clin. Pharmacol. 2025, 18, 837–846. https://doi.org/10.1080/17512433.2025.2587174.

  • 24.

    ACMD. ACMD Work Programme 2024; Advisory Council on the Misuse of Drugs: London, UK, 2024. Available online: https://www.gov.uk/government/publications/acmd-work-programme-2024 (accessed on 23 December 2025).

  • 25.

    ACMD. ACMD Work Programme 2025; Advisory Council on the Misuse of Drugs: London, UK, 2025. Available online: https://www.gov.uk/government/publications/acmd-work-programme-2025 (accessed on 23 December 2025).

  • 26.

    Kalk, N.J.; Chiu, C.T.; Sadoughi, R.; et al. Fatalities Associated with Gabapentinoids in England (2004–2020). Br. J. Clin. Pharmacol. 2022, 88, 3911–3917. https://doi.org/10.1111/bcp.15352.

  • 27.

    World Health Organization. The ICD 10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines; WHO: Geneva, Switzerland, 1992. Available online: https://iris.who.int/handle/10665/37958 (accessed on 23 December 2025).

  • 28.

    NRS. Drug-Related Deaths in Scotland Methodology Annexes; National Records of Scotland: Edinburgh, UK, 2025. Available online: https://www.nrscotland.gov.uk/media/lfzm3pbu/drug-related-deaths-methodology-annex.pdf (accessed on 6 February 2026).

  • 29.

    Corkery, J.M. Developments in the Epidemiology of Drug-Related Mortality in the United Kingdom over the Last 30 Years: Continuity, Change, Consistency, and Challenge. Ph.D. Thesis, University of Hertfordshire, Hatfield, UK, 2024. Available online: https://uhra.herts.ac.uk/id/eprint/15986/ (accessed on 6 February 2026).

  • 30.

    NRS. Drug Related Deaths in Scotland in 2024; National Records of Scotland: Edinburgh, UK, 2025. Available online: https://www.nrscotland.gov.uk/publications/drug-related-deaths-in-scotland-2024/ (accessed on 23 December 2025).

  • 31.

    MHRA. Interactive Drug Analysis Profiles for Gabapentin and Pregabalin; Medicines and Healthcare products Regulatory Agency: London, UK, 2025. Available online: https://yellowcard.mhra.gov.uk/idaps (accessed on 22 December 2025).

  • 32.

    Corkery, J.M.; Guirguis, A.; Chiappini, S.; et al. Alprazolam Related Deaths in Scotland, 2004–2020. J. Psychopharmacol. 2022, 36, 1020–1035. https://doi.org/10.1177/02698811221104065.

  • 33.

    Kelleher, C.; Riordan, F.; Gopalakrishnan, A. Drug Poisoning Deaths in Ireland in 2022: Data from the National Drug Related Deaths Index (NDRDI); HRB StatLink Series 28; Health Research Board: Dublin, Ireland, 2025.

  • 34.

    Mattson, C.L.; Chowdhury, F.; Gilson, T.P. Notes from the Field: Trends in Gabapentin Detection and Involvement in Drug Overdose Deaths—23 States and the District of Columbia, 2019–2020. MMWR Morb. Mortal. Wkly. Rep. 2022, 71, 664–666. https://doi.org/10.15585/mmwr.mm7119a3.

  • 35.

    Powell, D.; Shetty, K.D.; Peet, E.D. Trends in Overdose Deaths Involving Gabapentinoids and Z Drugs in the United States. Drug Alcohol Depend. 2023, 249, 109952. https://doi.org/10.1016/j.drugalcdep.2023.109952.

  • 36.

    Public Health Scotland. National Drug Related Death Database (Scotland): Analysis of Deaths Registered in 2019 and 2020; Public Health Scotland: Edinburgh, UK, 2024. Available online: https://publichealthscotland.scot/publications/national-drug-related-death-database-scotland/the-national-drug-related-deaths-database-scotland-report-analysis-of-deaths-registered-in-2019-and-2020/ (accessed on 23 December 2025).

  • 37.

    Darke, S.; Duflou, J.; Peacock, A.; et al. Characteristics of Fatal Gabapentinoid Related Poisoning in Australia, 2000–2020. Clin. Toxicol. 2022, 60, 304–310. https://doi.org/10.1080/15563650.2021.1965159.

  • 38.

    Chiappini, S.; Schifano, F. A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency’s “Suspected Adverse Drug Reactions” Database. CNS Drugs 2016, 30, 647–654. https://doi.org/10.1007/s40263-016-0359-y.

  • 39.

    MHRA. Gabapentin (Neurontin): Risk of Severe Respiratory Depression; Medicines and Healthcare products Regulatory Agency: London, UK, 2017. Available online: https://www.gov.uk/drug-safety-update/gabapentin-neurontin-risk-of-severe-respiratory-depression (accessed on 23 December 2025).

  • 40.

    Glancy, M.; Palmateer, N.; Yeung, A.; et al. Risk of Drug Related Death Associated with Co Prescribing of Gabapentinoids and Z Drugs among People Receiving Opioid Agonist Treatment: A National Retrospective Cohort Study. Psychiatry Res. 2024, 339, 116028. https://doi.org/10.1016/j.psychres.2024.116028.

  • 41.

    Vickers Smith, R.; Boland, E.M.; Young, A.M.; et al. A Qualitative Analysis of Gabapentin Misuse and Diversion among People Who Use Drugs in Appalachian Kentucky. Psychol. Addict. Behav. 2018, 32, 115–121. https://doi.org/10.1037/adb0000337.

  • 42.

    Applewhite, D.; Regan, S.; Koenigs, K.; et al. Use of Promethazine, Gabapentin, and Clonidine in Combination with Opioids or Opioid Agonist Therapies among Individuals Attending a Syringe Service Program. Int. J. Drug Policy 2020, 79, 102752. https://doi.org/10.1016/j.drugpo.2020.102752.

  • 43.

    Buttram, M.E.; Kurtz, S.P. Preliminary Evidence of Pregabalin Misuse among Prescription and/or Illicit Opioid Users. J. Psychoact. Drugs 2020, 52, 172–175. https://doi.org/10.1080/02791072.2020.1734695.

  • 44.

    Buttram, M.E.; Kurtz, S.P. Descriptions of Gabapentin Misuse and Associated Behaviors among a Sample of Opioid Users in South Florida. J. Psychoact. Drugs 2021, 53, 47–54. https://doi.org/10.1080/02791072.2020.1802087.

  • 45.

    Buttram, M.E.; Kurtz, S.P.; Dart, R.C.; et al. Law Enforcement Derived Data on Gabapentin Diversion and Misuse, 2002–2015: Diversion Rates and Qualitative Research Findings. Pharmacoepidemiol. Drug Saf. 2017, 26, 1083–1086. https://doi.org/10.1002/pds.4230.

  • 46.

    Buttram, M.E.; Kurtz, S.P.; Cicero, T.J.; et al. An Ethnographic Decision Model of the Initiation of Gabapentin Misuse among Prescription and/or Illicit Opioid Users. Drug Alcohol Depend. 2019, 204, 107554. https://doi.org/10.1016/j.drugalcdep.2019.107554.

  • 47.

    Chatterjee, A.; Lopez, D.; Ramkellawan, S.; et al. “That’s What We Call the Cocktail”: Non Opioid Medication and Supplement Misuse among Opioid Users. Subst. Abuse 2021, 42, 175–182. https://doi.org/10.1080/08897077.2019.1671943.

  • 48.

    Lyndon, A.; Audrey, S.; Wells, C.; et al. Risk to Heroin Users of Polydrug Use of Pregabalin or Gabapentin. Addiction 2017, 112, 1580–1589. https://doi.org/10.1111/add.13843.

  • 49.

    Snellgrove, B.J.; Steinert, T.; Jaeger, S. Pregabalin Use among Users of Illicit Drugs: A Cross Sectional Survey in Southern Germany. CNS Drugs 2017, 31, 891–898. https://doi.org/10.1007/s40263-017-0467-3.

  • 50.

    Baird, C.R.; Fox, P.; Colvin, L.A. Gabapentinoid Abuse in Order to Potentiate the Effect of Methadone: A Survey among Substance Misusers. Eur. Addict. Res. 2014, 20, 115–118. https://doi.org/10.1159/000355268.

  • 51.

    Ashworth, J.; Bajpai, R.; Muller, S.; et al. Trends in Gabapentinoid Prescribing in UK Primary Care Using the Clinical Practice Research Datalink: An Observational Study. Lancet Reg. Health Eur. 2023, 27, 100579. https://doi.org/10.1016/j.lanepe.2022.100579.

  • 52.

    Torrance, N.; Veluchamy, A.; Zhou, Y.; et al. Trends in Gabapentinoid Prescribing, Co Prescribing of Opioids and Benzodiazepines, and Associated Deaths in Scotland. Br. J. Anaesth. 2020, 125, 159–167.

  • 53.

    Xia, Y.; Forget, P. Opioid and Gabapentinoid Prescriptions in England from 2015 to 2020. PLoS ONE 2022, 17, e0276867. https://doi.org/10.1371/journal.pone.0276867.

  • 54.

    Rahman, A.; Kane, J.; Montastruc, F.; et al. Trends in New Prescription of Gabapentinoids and of Co Prescription with Opioids in the Four Nations of the UK, 1993–2017. Br. J. Clin. Pharmacol. 2021, 87, 3349–3353. https://doi.org/10.1111/bcp.14727.

  • 55.

    Lynn, E.; Cousins, G.; Lyons, S.; et al. A Repeated Cross Sectional Study of Factors Associated with Pregabalin Positive Poisoning Deaths in Ireland. Drug Alcohol Depend. 2020, 206, 107741. https://doi.org/10.1016/j.drugalcdep.2019.107741.

  • 56.

    Kriikku, P.; Ojanperä, I. Pregabalin and Gabapentin in Non Opioid Poisoning Deaths: A Postmortem Toxicology Study. Forensic Sci. Int. 2021, 327, 110990. https://doi.org/10.1016/j.forsciint.2021.110990.

  • 57.

    Muller, S.; Bailey, J.; Bajpai, R.; et al. Risk of Adverse Outcomes during Gabapentinoid Therapy and Factors Associated with Increased Risk in UK Primary Care Using the Clinical Practice Research Datalink: A Cohort Study. Pain 2024, 165, 2282–2290. https://doi.org/10.1097/j.pain.0000000000003239.

  • 58.

    Public Health England; NHS England. Advice for Prescribers on the Risk of the Misuse of Pregabalin and Gabapentin; Public Health England & NHS England: London and Redditch, UK, 2014. Available online: https://www.gov.uk/government/publications/pregabalin-and-gabapentin-advice-for-prescribers-on-the-risk-of-misuse (accessed on 23 December 2025).

  • 59.

    Gomes, T.; Juurlink, D.N.; Antoniou, T.; et al. Gabapentin, Opioids, and the Risk of Opioid Related Death: A Population Based Nested Case–Control Study. PLoS Med. 2017, 14, e1002396. https://doi.org/10.1371/journal.pmed.1002396.

Share this article:
Download PDF
DOI
10.53941/cna.2026.100007
Issue
Volume 2, Issue 2
How to Cite
Corkery, J. M.; Guirguis, A.; Schifano, F. Deaths Involving Gabapentin and Pregabalin, Scotland, 2000–2024: A Descriptive Account. Clinical Neuropsychopharmacology and Addiction 2026, 2 (2), 7. https://doi.org/10.53941/cna.2026.100007.
RIS
BibTex
Copyright & License
article copyright Image
Copyright (c) 2026 by the authors.